Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

381

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

381 results for “acute respiratory distress syndrome”

Learn how ShareScore rates datasets ↗
zenodo48/100

DATA SET: Peripheral microcirculatory alterations are associated with the severity of acute respiratory distress syndrome in COVID-19 patients admitted to intermediate respiratory and intensive care units

<p>This repository contains the data sets of the article:</p> <p>Mesquida, J., Caballer, A., Cortese, L.&nbsp;<em>et al.</em>&nbsp;Peripheral microcirculatory alterations are associated with the severity of acute respiratory distress syndrome in COVID-19 patients admitted to intermediate respiratory and intensive care units.&nbsp;<em>Crit Care</em>&nbsp;<strong>25,&nbsp;</strong>381 (2021). https://doi.org/10.1186/s13054-021-03803-2</p>

opencc-by-4.0Nov 2021View details →
zenodo44/100

Acute Respiratory Distress Syndrome-Database of Genes (ARDS-DB)

<p>To better understand the gene level associations that are most relevant to Acute Respiratory Distress Syndrome (ARDS), a comprehensive resource is needed.&nbsp; There&rsquo;s currently no freely available database dedicated to ARDS that provides comprehensive gene lists from experimentally verifiable studies, gene function, gene location, and additional metadata for tracking related link out resources.&nbsp; The need for such a database is only accentuated by the steep rise in ARDS cases due to the 2020&nbsp;Coronavirus pandemic, in which infected patients admitted to the ICU develop ARDS at a rate of 67% to 85%, calling for an increase into ARDS research.&nbsp;</p> <p>Our goal was to develop such a resource for use by the scientific community to enhance our studies of ARDS and associated genes.&nbsp; Our first step was to perform data mining and curation of scientific literature through a robust review process.&nbsp; Subsequent steps enabled us to refine our data by capturing specific metadata and incorporating these into our database.&nbsp; The version 1 of the database will provide users with access to the database flat file with current genes, gene location, chromosomal information, and more in a freely accessible and downloadable format. Future project goals are to develop a standalone web portal that will integrate the gene level information with network analysis, and other visualizations for users.&nbsp;</p> <p>&nbsp;</p>

opencc-by-4.0Sep 2020View details →
Figshare44/100

Dataset for the paper "Prolonged prothrombin time as an early prognostic indicator of severe acute respiratory distress syndrome in patients with COVID-19 related pneumonia"

<p>The dataset contains the data on ICU-transferred (N=100) and Stable (N=131) patients with COVID-19 (N=156) and Non-COVID-19 viral pneumonia (N=75). Among COVID-19 patients of this study, 82 patients developed Refractory Respiratory Failure (RRF) or Severe Acute Respiratory Distress Syndrome (SARDS) and were transferred to Intensive Care Unit (ICU), 74 patients had a Stable course of disease and were not transferred to ICU. Collected data are presented as a table with columns:<br> - Gender;<br> - Age (years);<br> - SARS-CoV-2 RT-PCR testing results;<br> - Time between the disease onset and admission to the hospital (days);<br> - Time between admission to the hospital and transfer to ICU (days);<br> - Artificial lung ventilation in ICU needed;<br> - C-reactive protein (CRP) upon admission (mg/L);<br> - International Normalized Ratio (INR) upon admission;<br> - Prothrombin Time (PT) upon admission (sec.);<br> - Fibrinogen upon admission (mg/L);<br> - Chest Computed Tomography (CT) upon admission: lung tissue affected (%);<br> - Platelet count upon admission (10^9/L);<br> - Chest CT, 1 week after admission: lung tissue affected (%);<br> - CRP, 1 week after admission (mg/L);<br> - Platelet count, 1 week after admission (10^9/L).</p>

opencc-by-4.0Dec 2019View details →
zenodo40/100

Unveiling Pathophysiological Insights: Serum Metabolic Dysregulation in Acute Respiratory Distress Syndrome Patients with Acute Kidney Injury

<p>The uploaded data is an Excel sheet obtained after performing the binning of 1H CPMG NMR spectra acquired using 800 MHz NMR on the serum samples of ARDS patients and ARDS with AKI patients.&nbsp;</p>

opencc-by-4.0Jul 2024View details →
zenodo40/100

The impact of severity of acute respiratory distress syndrome following cardiac arrest on neurologic outcomes

<p>Overall survival rates at 28 days in patients with and without ARDS. ARDS = acute respiratory distress syndrome</p>

opencc-by-4.0Sep 2019View details →
ClinicalTrials.gov40/100

Linking Endotypes and Outcomes in Pediatric Acute Respiratory Distress Syndrome

ClinicalTrials.gov study NCT04113434. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
zenodo36/100

Pharmacokinetic dataset of a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19

<p>Abstract</p> <p>Background</p> <p>The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition characterized by widespread inflammation and vascular leak in the lungs. Although there is no proven therapy to reduce pulmonary vascular leak in ARDS, recent studies demonstrated that the tyrosine kinase inhibitor imatinib reinforces the endothelial barrier and prevents vascular leak in inflammatory conditions, while leaving the immune response intact.</p> <p>Methods</p> <p>This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter clinical trial of intravenous (IV) imatinib mesylate in 90 mechanically ventilated subjects with COVID-19-induced ARDS. Subjects are 18&thinsp;years or older, admitted to the ICU for mechanical ventilation, meeting the Berlin criteria for moderate-severe ARDS with a positive polymerase chain reaction test for SARS-CoV2. Participants will be randomized in a 1:1 ratio to either imatinib (as mesylate) 200&thinsp;mg bis in die (b.i.d.) or placebo IV infusion for 7&thinsp;days, or until ICU discharge or death. The primary study outcome is the change in Extravascular Lung Water Index (EVLWi) between day 1 and day 4. Secondary outcome parameters include changes in oxygenation and ventilation parameters, duration of invasive mechanical ventilation, number of ventilator-free days during the 28-day study period, length of ICU stay, and mortality during 28&thinsp;days after randomization. Additional secondary parameters include safety, tolerability, and pharmacokinetics.</p> <p>Discussion</p> <p>The current study aims to investigate the efficacy and safety of IV imatinib in mechanically ventilated subjects with COVID-19-related ARDS. We hypothesize that imatinib decreases pulmonary edema, as measured by extravascular lung water using a PiCCO catheter. The reduction in pulmonary edema may reverse hypoxemic respiratory failure and hasten recovery. As pulmonary edema is an important contributor to ARDS, we further hypothesize that imatinib reduces disease severity, reflected by a reduction in 28-day mortality, duration of mechanical ventilation, and ICU length of stay.</p>

opencc-by-4.0Jun 2023View details →
ClinicalTrials.gov36/100

Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)

ClinicalTrials.gov study NCT04870125. IPD Sharing: YES. Countries: 1. Publications: 12.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Sigh Ventilation to Increase Ventilator-Free Days in Victims of Trauma at Risk for Acute Respiratory Distress Syndrome

ClinicalTrials.gov study NCT02582957. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Electrical Impedance Tomography for Optimization of Positive End-Expiratory Pressure: Acute Respiratory Distress Syndrome

ClinicalTrials.gov study NCT03793842. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)

ClinicalTrials.gov study NCT04530604. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome

ClinicalTrials.gov study NCT01438853. IPD Sharing: Not stated. Countries: 2. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Intensive Nutrition in Acute Respiratory Distress Syndrome (ARDS): A Clinical Trial (INTACT)

ClinicalTrials.gov study NCT01921101. IPD Sharing: Not stated. Countries: 1. Publications: 8.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Human Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome (START)

ClinicalTrials.gov study NCT02097641. IPD Sharing: NO. Countries: 1. Publications: 4.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Exploration of Diagnosis and Treatment Strategies and Prognostic Prediction Models for Acute Respiratory Distress Syndrome Based on Radiographic Evaluations Assessed by Artificial Intelligence

ClinicalTrials.gov study NCT07328997. IPD Sharing: YES. Countries: 1. Publications: 30.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Mesenchymal Stromal Cells For Acute Respiratory Distress Syndrome

ClinicalTrials.gov study NCT03818854. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)

ClinicalTrials.gov study NCT04351243. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Pediatric Acute Respiratory Distress Syndrome Asia Study

ClinicalTrials.gov study NCT04068038. IPD Sharing: UNDECIDED. Countries: 10. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS)

ClinicalTrials.gov study NCT04581811. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)

ClinicalTrials.gov study NCT02622724. IPD Sharing: NO. Countries: 8. Publications: 2.

closedIPD-NOFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record